Literature DB >> 23993213

Comparison of 3 Etest(®) methods and time-kill assay for determination of antimicrobial synergy against carbapenemase-producing Klebsiella species.

George A Pankey1, Deborah S Ashcraft, Adriana Dornelles.   

Abstract

Increasing global antibiotic resistance has resulted in more use of antibiotic combinations. There is a lack of a gold standard for in vitro testing of these combinations for synergy or antagonism. Time-kill assay (TKA) may be used but is labor intensive and not practical for clinical use. Etest® synergy methods are more rapid and easier to perform, but there is no agreement regarding which method is best. We tested 31 clinical genetically unique Klebsiella pneumoniae carbapenemase-producing Klebsiella isolates with the combination of meropenem and polymyxin B by TKA and 3 Etest methods, each in triplicate: Method 1, MIC:MIC; Method 2, direct overlay; and Method 3, cross. Overall, testing with Etest synergy methods showed the following agreement with TKA: Method 1: 25/31 (80.6%), Method 2: 7/31 (22.6%), and Method 3: 8/31 (25.8%). The MIC:MIC method had the highest agreement (80.6%, κ = 0.59, P < 0.001) and should be evaluated more extensively.
© 2013.

Entities:  

Keywords:  Etest; Klebsiella; Synergy

Mesh:

Substances:

Year:  2013        PMID: 23993213     DOI: 10.1016/j.diagmicrobio.2013.07.006

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  9 in total

1.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2013

2.  Infective endocarditis due to Streptococcus dysgalactiae: clinical presentation and microbiological features.

Authors:  Anna Bläckberg; Bo Nilson; Volkan Özenci; Lars Olaison; Magnus Rasmussen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-08       Impact factor: 3.267

3.  Time-kill assay and Etest evaluation for synergy with polymyxin B and fluconazole against Candida glabrata.

Authors:  George Pankey; Deborah Ashcraft; Heather Kahn; Abdulrahim Ismail
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

4.  Clinical and microbiological features of infective endocarditis caused by aerococci.

Authors:  Torgny Sunnerhagen; Bo Nilson; Lars Olaison; Magnus Rasmussen
Journal:  Infection       Date:  2015-06-29       Impact factor: 3.553

5.  Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria.

Authors:  Abiu Sempere; Belén Viñado; Ibai Los-Arcos; David Campany; Nieves Larrosa; Nuria Fernández-Hidalgo; Dolors Rodríguez-Pardo; Juan José González-López; Xavier Nuvials; Benito Almirante; Laura Escolà-Vergé
Journal:  Antimicrob Agents Chemother       Date:  2022-09-14       Impact factor: 5.938

6.  Candida glabrata complex from patients with healthcare-associated infections in Mansoura University Hospitals, Egypt: distribution, antifungal susceptibility and effect of fluconazole and polymyxin B combination.

Authors:  Ghada Mashaly; Raghdaa Shrief
Journal:  Germs       Date:  2019-09-02

7.  Infective Endocarditis Due to Corynebacterium Species: Clinical Features and Antibiotic Resistance.

Authors:  Anna Bläckberg; Linn Falk; Karl Oldberg; Lars Olaison; Magnus Rasmussen
Journal:  Open Forum Infect Dis       Date:  2021-02-04       Impact factor: 3.835

Review 8.  When One Drug Is Not Enough: Context, Methodology, and Future Prospects in Antibacterial Synergy Testing.

Authors:  Thea Brennan-Krohn; James E Kirby
Journal:  Clin Lab Med       Date:  2019-06-12       Impact factor: 1.935

9.  Comparison of methods for the detection of in vitro synergy in multidrug-resistant gram-negative bacteria.

Authors:  Juliana Januario Gaudereto; Lauro Vieira Perdigão Neto; Gleice Cristina Leite; Evelyn Patricia Sanchez Espinoza; Roberta Cristina Ruedas Martins; Gladys Villas Boa Prado; Flavia Rossi; Thais Guimarães; Anna Sara Levin; Silvia Figueiredo Costa
Journal:  BMC Microbiol       Date:  2020-04-16       Impact factor: 3.605

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.